Interestingly, the cancer cell-directed STINGa ADC (which delivers STINGa into both immune cells and cancer cells) retains its potent cancer-cell-killing activity in STING KO cancer cells in co-cultures with immune cells at high doses, but its activity is reduced at low doses or when immune cells are sparse. Here, STING1 is linked to cancer.